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Reports of interstitial deletions involving proximal long arm of chromosome 2 are limited. Based on early chromosomal
analysis studies, the phenotypic consequence of deletions at the ancestral chromosome fusion site at chromosome
2q13q14.1 remains unclear. A recurrent 1.71 Mb deletion at 2q13 has recently been proposed as a new genomic
disorder, associated with an increased risk of intellectual disability and craniofacial dysmorphism. Herein, we report the
case of a 12 year-old girl with unique clinical features including global developmental delay, mullerian agenesis, and
hypothyroidism associated with a normal size and position of the thyroid gland, as well as negative thyroid antibodies.
Microarray-based comparative genomic hybridization study revealed a de novo 10.79 Mb deletion at 2q13q14.2
(111,548,932–122,336,492), which involves more than 88 UCSC genes, 38 of which are OMIM genes, 7 of which are
disease-causing and 3 of which (including GLI2, IL1B and PAX8) show a dominant inheritance pattern.. Interestingly,
PAX8 (chr2:113,973,574–114,036,498), a member of the paired-box gene family, is essential for the formation of
thyroxine-producing follicular cells. Autosomal dominant transmission of congenital thyroid hypoplasia due to loss-of-
function mutation of PAX8 suggests a possible haploinsufficiency effect. Additionally, PAX8 is also expressed in the tissue
primordia that form both the mullerian duct derivatives and the upper urinary tracts. A recent study has associated a
novel PAX8 mutation with a severe form of hypothyroidism and abnormalities in the urogenital tract. Taken together,
the unique clinical manifestation seen in this patient could be attributed to the heterozygous deletion of PAX8 gene. A
prospective investigation is merited to fully evaluate the pathogenic effect of the interstitial deletion of 2q13q14.2.
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Recombination is the main cause of genetic diversity. Errors
in recombination lead to a variety of chromosomal abnor-
malities [1]. Through the application of microarray compara-
tive genomic hybridization (aCGH) technology, identification
of both recurrent and atypical genomic alterations, such as
copy number variants becomes a conventional approach for
discovering new genomic disorders and mapping dosage sen-
sitive genes [2]. In the era of personalized genome medicine,* Correspondence: dema@montefiore.org; RNAEEM@montefiore.org
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unless otherwise stated.this technique allows the molecular characterization of the
breakpoints at a finer scale [3,4], which ultimately will
improve the delivery of healthcare for individuals affected
with these abnormalities.
The proximal long arm of chromosome 2 contains the
ancestral chromosome fusion site at 2q13q14.1 [5]. Stud-
ies examining genotype-phenotype correlations at this
site, are limited. For instance, based on early chromo-
somal and FISH studies, the phenotypic consequence of
2q13q14.1 deletion is not well known [6-9]. Recently, an
aCGH-based study proposed a 1.71 Mb recurrent gen-
omic disorder at 2q13 (111392197–113102594) [10],
which is linked to an increased risk of intellectual dis-
ability and craniofacial dysmorphism; a wide range of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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affected with this deletion. Studies of atypical deletions
in this region have furthered the understanding of
genotype-phenotype correlation through cases with
distinct clinical features including pontine tegmental
cap dysplasia involving NPHP1 gene (chr2:110862477–
110959127) [11], gastrointestinal tumours involving
BUB1 gene (chr2:111399043–113102735) [12], congenital
heart defect involving FBLN7 and TMEM87B gene
(chr2:111442130–113937615) [13] and chronic cutaneous
pustulosis, a newly recognized disease caused by 175 kb
deletion involving IL1RN and five adjacent genes (IL1F9,
IL1F6, IL1F8, IL36RN, and IL1F10) [14].
Herein we report the case of a 12-year-old girl with
multiple congenital and developmental anomalies, who
was found to be carrying a de novo 10.79 Mb interstitial
deletion at 2q13q14.2 (111,548,932–122,336,492), which
involves PAX8 gene. Novel features found in this pa-
tient include mullerian agenesis (also known as Mayer-
Rokitansky-Küster-Hauser syndrome, or the Rokitansky




C.N was the second child born to healthy, non-
consanguineous parents; her mother was 28 years of age at
the time of her birth. Family history was non-contributory.
The pregnancy was complicated by oligohydramnios and
reduced fetal movements. Amniocentesis was normal. She
was born via an uncomplicated elective Cesarean section
due to a previous Cesarean section in a hospital in the
Dominican Republic at 37 weeks of gestation, with a
birth weight of 6.75 lbs. Apgar scores were 9 at one mi-
nute and 10 at 5 minutes. Neonatal course was uncom-
plicated and she was discharged from the well-baby
nursery on the fourth day of life (the nursery stay elon-
gated because of the mother’s caesarean section).
Signs of developmental delay were apparent to the par-
ents by 2–4 months. CN began sitting independently at
12 months and walked at two and half years of age; be-
cause of these delays, she was referred for early interven-
tion services and received occupational, physical and
speech therapies, each two times per week. During her
first two years, scoliosis was diagnosed, and she experi-
enced recurrent episodes of otitis media requiring the
placement of tympanostomy tubes.
CN came to the US with her family at age 2. During
childhood, she was noted to have short stature and some
craniofacial dysmorphic features. A preliminary work-up
revealed an elevated level of thyroid stimulating hor-
mone (TSH), with thyroid hormone (T4) levels in the
normal range. On the basis of these findings, she was re-
ferred for evaluation to endocrinology.At endocrine clinic, initial laboratory investigations re-
vealed normal chemistry, liver function tests, celiac
screen, and IGF-1 level. Testing confirmed an elevated
TSH (9.610 uIU/ml [0.70–5.70]) with a low normal free
T4 level (0.92 ng/dl [0.80–1.90]) and negative thyroid
antibodies. Her gonadotropins were normal with a de-
layed bone age. Initial pelvic sonogram showed normal
prepubertal uterus with no visualization of ovaries. Cyto-
genetic analysis (metaphase banded chromosomes) was
interpreted as normal. The patient was begun on thyroid
hormone supplementation.
CN was followed over several months for short stature
and maintained on 50mcg synthroid. Repeat thyroid
function tests revealed that with treatment, she was in
the euthyroid range. Because of severe right lower quad-
rant pain, she was brought to the emergency department
for evaluation. Work-up revealed torsion of her right fal-
lopian tube, a blind vaginal pouch, and a prepubertal
hemiuterus with normal-appearing kidneys. She under-
went emergency surgery with right salpingectomy and
hemiuterus resection. A growth hormone stimulation test
with clonidine and arginine was done 1 month thereafter
with normal cortisol and growth hormone response.
Because of her multiple anomalies, associated with in-
tellectual disabilities and short stature, CN was referred
to genetics clinic for evaluation.
Physical examination
Examination in genetics clinic at 12 years of age showed
a weight of 34.8 kg (8th percentile), height of 139.8 cm
(<3rd percentile), and an occipitofrontal circumference
(OFC) of 51.3 cm (50th percentile). Facial features in-
cluded slight frontal bossing, deeply set eyes, long nose
with a bulbous tip, large protruding ears, and long eye-
lashes (Figure 1). She also had hypotonia, clinodactyly of
the fifth fingers bilaterally, hallux valgus, cubitus valgus,
pes planus and hypoplastic palmar crease pattern bilat-
erally without apparent dermatoglyphic abnormalities.
Skin examination revealed no lesions. She demonstrated
Tanner 4 breast and pubic hair development. Mild scoli-
osis was appreciated.
Thyroid sonography
A sonogram of the thyroid was performed assessing gray
scale appearance and color Doppler flow. The right lobe
measures as 1.4 × 2.4 × 0.7 cm. The left lobe measures
as 1.3 × 3 × 0.9 cm. The thyroid gland was homoge-
neous in echo texture. There is no discrete mass or cyst
and normal vascularity was noted. The isthmus mea-
sures as 0.2 cm in thickness. No isthmus nodule is seen.
Chromosome analysis
Standard methods were followed while performing
culturing, harvesting of peripheral blood cells and
Figure 1 Patient images. Facial anomalies limited to slight frontal bossing, deeply set eyes, long nose with a bulbous tip, large protruding ears,
and long eyelashes and clinodactyly.
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studied and the karyotype was interpreted according to
the International System for Human Cytogenetic No-
menclature (ISCN 2013). Retrospective cytogenetic
analysis revealed a band deletion at 2q13q14 (Figure 2A)
at the 550 band level.A
B
Arr2q13q14.2 (111,548,932-122,336,492)x1
Figure 2 Chromosome and aCGH findings. A: chromosome analysis; B:
deletion regions.Microarray-Comparative Genomic Hybridization (aCGH)
aCGH was carried out using the Agilent Human Genome
CGH Microarray Kit (Agilent Technologies, Santa Clara,
California, USA). DNA was labeled using Agilent Suretag
DNA Labeling Kit, and applied to 44 K oligonucleotide








Array-CGH profile of chromosome 2; C: OMIM morbid genes within the
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Extraction and Cytogenomics 2.7 software packages [ADM-
2 algorithm employed] (Agilent, USA). A 10.79 Mb
deletion at 2q13-14.2 (111,548,932–122,336,492) [hg19]
(Figure 2B), which is consistent with the result from
cytogenetic analysis (Figure 2A). Parental aCGH studies
were normal, indicating that the deletion in the pro-
band occurred de novo.
Discussion
As mentioned above, only a few cases with a proximal
interstitial deletion at chromosome 2q13q14 have been
previously reported. A review of these cases reveals
contradictory phenotytpic findings. Individuals with this
deletion demonstrate a wide spectrum of clinical fea-
tures ranging from no obvious abnormalities, through
mildly dysmorphic feature to severe intellectual disabil-
ities and multiple congenital malformations [6-9]. Since
in the past, breakpoint mapping has been based on
karyotype and FISH results, direct comparisons with our
case are not possible. A comprehensive search in our in-
ternal, DECIPHER and ISCA databases failed to identify
any cases carrying a deletion that overlapped with the
PAX8 gene or in which a similar clinical presentation to
the case being reported here was identified. Thus, this is
the first report of a patient carrying a 10.79 Mb deletion
at 2q13q14.2 (111,548,932–122,336,492) in which unique
clinical features, including global intellectual disability,
mullerian agenesis, and hypothyroidism with a normal size
and position of the thyroid, have been identified. The mo-
lecular characterization of the large deletion at 2q13q14.2
provides a clue for the etiology of the hypothyroidism and
mullerian agenesis and potential strategies for future
surveillance.
The de novo deletion identified in patient CN overlaps
with the previously reported genomic deletion at chromo-
some 2q13 (111392197–113102594) [10]. The currently
described deletion involves more than 88 UCSC genes,
38 of which are OMIM genes and seven of which are
OMIM morbid (Figure 2C). Among the seven disease-
causing genes, a recessive mode of inheritance has been
reported for MERTK (Proto-oncogene tyrosine kinase
MER), IL36RN (Interleukin 36 receptor antagonist),
RNU4ATAC (Small nuclear RNA 4atac) and IL1RN
(Interleukin 1 receptor antagonist), while an autosomal
dominant pattern is documented for PAX8 (Paired box
gene 8), GLI2 (GLI-Kruppel family member 2) and IL1B
(Interleukin 1-Beta). Loss-of-function mutations inherited
in a dominant fashion have been documented in OMIM
for PAX8 and GL12, suggesting a possible haploinsuffi-
cency of their proteins.
Congenital hypothyroidism (CH) is a condition that af-
fects infants from birth (congenital) and results from a
partial or complete loss of thyroid function. The mostcommon congenital endocrine disorder, it has been
noted to affects 1 in 2700 newborns, according to a re-
cent European survey [15]. In between 80 and 85 percent
of cases, the thyroid gland is absent, abnormally located,
or hypoplastic. In the remaining cases, a normal-sized or
enlarged thyroid gland is present, but production of thy-
roid hormones is decreased or absent [16]. The candidate
genes associated with this genetically heterogeneous dis-
order are classified into two main groups: those causing
thyroid gland dysgenesis and those causing dyshormono-
genesis. Genes associated with thyroid gland dysgenesis
include the TSH receptor in non-syndromic CH, and
Gsalpha and the thyroid transcription factors (TTF-1,
TTF-2, and PAX8), associated with different complex syn-
dromes that include CH [17]. However, thyroid morph-
ology of those mutation carriers is variable (i.e. normal to
severe hypoplasia). So far, the only systematic genetic
screening of patients with CH is a study from Japan, in
which 102 newborns with CH, who are either with or
without thyroid dysgenesis (TD) revealed that PAX8
mutations are the leading cause with a prevalence of
2% in the cohort among the mutations of four tran-
scription factors including PAX8, NKX2-1 [encoding
thyroid transcription factor (TTF)-1], FOXE1 (encoding
TTF-2), and NKX2-5, [18].
PAX8 is a member of the paired-box gene family and
expressed in embryogenesis of the thyroid, Mullerian
and renal/upper urinary tracts, as well as in carcinomas
from each of these sites [19,20]. It regulates the expres-
sion of genes encoding thyroglobulin (TG), thyroid per-
oxidase (TPO), and the sodium-iodide symporter (NIS)
by binding to the promoter regions through its 128-
amino acid paired domain [21,22], which is essential for
the formation of thyroxine-producing follicular cells. Its
point mutations and small indels are recognized causes
of CH mainly through a loss-of-function effect [23];
however, some cases can present with a normal sized
thyroid gland [24], which is the case for our patient.
Additionally, although it usually occurs in isolation,
CH is also seen as a part of multiple congenital malfor-
mation syndromes, predominantly associated with con-
genital heart disease, neural tube defects and dysmorphic
features [25,26]. PAX8-specific extrathyroid malformation
syndrome has recently been reported in a multi-generation
family in which six members were found to carry a
novel heterozygous point mutation (c.74C > G). Fea-
tures of this condition combine a severe form of con-
genital hypothyroidism with urogenital malformations,
including incomplete horseshoe kidney and hydrocele
present in females as well as undescended testicles and
ureterocele in males [27]. For our patient in whom a
complete one-copy deletion of PAX8 was identified,
extrathyroid malformations of the urogenital tract included
Rokitansky sequence (mullerian agenesis) associated with
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tion was found in the kidneys.
GL12 and IL1B are two other genes in the deleted region
that demonstrate autosomal dominant modes of inherit-
ance. The GLI2 transcription factor is a major effector
protein of the sonic hedgehog pathway and has been re-
ported to play a key role in pituitary development [28].
Mutations in this gene are associated with anterior pituit-
ary hypoplasia and, frequently, ectopy of the posterior lobe
of the pituitary results [29]. Genomic GLI2 aberrations
that mainly result in truncated proteins have been re-
ported to cause holoprosencephaly or holoprosencephaly-
like features, sometimes associated with hypopituitarism
[30]. GLI2 mutations with proven pathogenic impact have
all been either heterozygous of nonsense orframeshift mu-
tations, all leading to truncated proteins lacking a func-
tional C-terminal transactivation domain. Loss of function
has been demonstrated for some of them by distinct
in vitro approaches, but experimental reasoning is so far
limited to the mutations identified by Roessler et al.
[31,32]. In general, the phenotype of GLI2 mutations is
variable, and penetrance is incomplete as further sug-
gested by a recent family segregation study, in which the
proband carried a 1.3 Mb deletion encompassing GLI2
gene [33]. Our patient apparently does not demonstrate
features of either holoprosencephalyor hypopituitarism..
The human interleukin 1-Beta (IL1B) gene plays an
important role in responding to microbial invasion, in-
flammation, immunologic reactions, and tissue repair
[34]. Our patient presented with recurrent ear infections,
which could be related to lack of IL1B. Loughlin, et al.
describes IL-1 gene cluster at 2q13 as being the main
catabolic cytokine of the joint with osteoarthritis, and
can stimulate synthesis of proteinases, which can cause
the breakdown of cartilage extracellular matrix proteins
[35]. A prospective surveillance may be necessary to
evaluate the possible pathogenic effect via haploinsuffi-
ciency of IL1B in the patient.
Conclusion
This case is an example of a commonly-occurring prob-
lem: a child with multiple congenital anomalies in whom
a unifying diagnosis is not obvious. Although the im-
portance of using aCGH as a first-tier diagnostic tool in
individuals with unexplained developmental delay and
unusual phenotypes cannot be overstated, use of aCGH
to identify a CNV in such a patient would provide the
opportunity for early diagnosis, providing the possibility
of early treatment and genetic counseling for the family.
In the present case, the very unique manifestation of the
non-autoimmune and possible congenital hypothyroidism
with a normal size and position of thyroid and mullerian
agenesis could be attributed to the heterozygous deletion
of PAX8 gene in this case. A prospective investigation ismerited to fully evaluate the pathogenic effect of the inter-
stitial deletion of 2q13q14.2.
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